Medisse is currently preparing for the clinical phase of the FlexiSurge® Adhesion Barrier, which is slated to start in 2012. In parallel, Medisse is developing further resorbable soft tissue implants, based on its proprietary PTMC technology platform. With a full and sustainable development pipeline for the coming years, Medisse and its current investors are looking for partners to expand the development of the company’s product portfolio and support the company’s product launches planned for 2013 and thereafter.
If you are investing in medical device companies and are looking for an interesting investment opportunity, Medisse offers a strong and novel platform technology for a variety of resorbable medical devices. Our team has many years of experience in developing and commercialising medical devices, and combines its unique expertise to leverage the unique bio-material properties of Poly(1,3-Trimethylene Carbonate) in various implants, covering many different surgical areas. Please contact us at Investors@medisse.com for further information.